ARPO Aerpio Pharmaceuticals Inc

DGAP-News: Nutricion Center NC and ADL Bionatur Solutions sign a strategic alliance to tackle weight control by rebalancing the gut microbiome

DGAP-News: ADL Bionatur Solutions / Key word(s): Alliance
Nutricion Center NC and ADL Bionatur Solutions sign a strategic alliance to tackle weight control by rebalancing the gut microbiome

19.02.2019 / 11:31
The issuer is solely responsible for the content of this announcement.


Nutricion Center NC and ADL Bionatur Solutions sign a strategic alliance to tackle weight control by rebalancing the gut microbiome

- First age-specific products for weight control by addressing the gastrointestinal microbiome

- ADL Bionatur Solutions, by partnering with Nutricion Center NC, opens up big opportunities in the Spanish pharmacy sector: reaching over 2,000 direct sales points, and 20,000 pharmacies

León, Spain, 19th February 2019 - Nutricion Center NC, a specialist in nutrition services for pharmacies, today announced entering into a strategic alliance with ADL Bionatur Solutions (MAB: ADL), a company specialized in research and development of healthcare products, services and industrial fermentation production. The partners plan to launch a new generation of products that help to control weight by addressing the gastrointestinal microbiome. The new product range "100% NC Microbiota", jointly developed by both companies, offers treatments with differing combinations of probiotics, as modulating agents, provided by ADL. The personalized combinations are adapted for the first time to each age range and particular function, for example: anti-obesity; diuretic; antioxidant; or satiating.

Pilar de la Huerta, CEO of ADL Bionatur Solutions, commented: "We are delighted to enter this strategic alliance with Nutricion Center NC, which is ADL's first step towards our goal of developing a proprietary pipeline of products aimed at the human microbiome. Entering the pharmacy channel in Spain brings us closer to the end-consumer. ADL is committed to its integrated health concept, in which personalized preventive medicine based on high value-added food supplements is increasingly important and promises great potential for future growth."

Antonio González, CEO of the Nutricion Center NC, added: "This alliance between Nutricion Center NC and ADL Bionatur Solutions is a strategic collaboration that will bring new treatments for the human intestinal microbiome to build positive effects on our general well-being. The supplements we offer are essential to optimize the effectiveness of treatments against obesity, while also, addressing the problems suffered by overweight people, providing extra benefits for each age group."

The human microbiome, refers to the set of microorganisms, composed mostly of bacteria, which live in the intestine, skin and mucous membranes of our body. The microbiome is crucial for helping to maintain an adequate functionality of the intestinal mucosa, which results in the healthy digestion of beneficial substances and less impact of substances with undesirable effects. It also plays a central role in diseases such as obesity, diabetes and inflammatory bowel disease (IBD) and could have important implications for development of chronic diseases and response to treatments. Thus, a balanced microbiome is considered essential for the individual to respond to weight control measures.

The innovative 100% NC Microbiota products for weight control are divided into three lines for different age groups, each product line comprising products that act as abdominal fat burners, body fat burners, fat blockers, drains, antioxidant-drainers and appetite inhibitors, complemented with specific probiotic strains intended for balancing the gut microbiome.

About Nutricion Center NC
Nutricion Center NC
was founded in 1988 with the introduction of Nutricion Center in pharmacies. Due to the evolution of the company it has become a reference in the weight control sector. Thanks to this, the company has created its innovative Integral Beauty Service, with dietetic treatments for weight control and maintenance as well as dermo-dietetics. The main objective of the services offered by Nutricion Center NC is teaching people how to eat properly and introduce healthy habits in their everyday life, which help them to feel healthy and, above all, happy with themselves. Furthermore, it has 300 professionals providing advice in more than 3,000 pharmacies throughout Spain, and an online platform (), where doctors, consultants, psychologists, personal trainers and cooks help achieve the goal of weight control.

About ADL Bionatur Solutions
ADL Bionatur Solutions (MAB: ADL)
is a company specialized in biopharma manufacturing plus research and development targeting the human microbiome and the animal health sector. The Company, which owns the largest fermentation production plant in Southern Europe, carries out high value-added product development, scale-up and production for third parties. International healthcare companies as well as first-in-class academic and industrial laboratories, mainly from Europe and the US, are part of ADL's customer base. The biopharma manufacturing business is complemented by a research and development division, which creates a proprietary product pipeline in animal and human health. ADL is listed on MAB, Spain's Alternative Stock Market (ISIN ES0184980003) and its major shareholder is the investment fund Black Toro Capital holding 73%. More information is available at

For more information please contact:

ADL Bionatur Solutions
Blanca San Román
IRO and Communications
Email:

International Media & Investor Relations
MC Services AG
Raimund Gabriel
Tel.:
Email:

For more information Nutricion Center NC:

Nutricion Center NC
Tel. 1


Eolo Comunicación
Press office
Alicia de la Fuente

María del Carmen Sisto

Tel. 6  /



19.02.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


777265  19.02.2019 

fncls.ssp?fn=show_t_gif&application_id=777265&application_name=news&site_id=research_pool
EN
19/02/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch